{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"80.96","upperLimit":"92.92","value":"88.29"},{"groupId":"OG001","lowerLimit":"82.63","upperLimit":"94.77","value":"90.37"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"127"}],"units":"Participants"}],"description":"OS rates of LR relapse B-ALL patients who are randomized following Block 1 chemotherapy to receive either chemotherapy alone or chemotherapy plus blinatumomab (LR Randomization). OS is calculated as the time from randomization to date of death or date of last contact. Three-year OS estimates will be calculated from date of randomization for both Arm C and Arm D. Two-sided 95% confidence intervals will be calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, Continuation 1 over 8 weeks, Continuation 2 over 8 weeks, and then Maintenance. CNS3 patients receive chemoradiation post-Maintenance Cycle 1. Patients with persistent testicular involvement after Block 1 receive testicular radiation during Block 2.","id":"OG000","title":"Arm C (LR Control)"},{"description":"Patients receive Block 2 over 4 weeks, Blinatumomab Cycle 1 over 5 weeks, Continuation 1 over 8 weeks, Blinatumomab Cycle 2 over 5 weeks, Continuation 2 over 8 weeks, Blinatumomab Cycle 3 over 5 weeks, and then Maintenance. CNS3 patients receive chemoradiation post Maintenance Cycle 1. Patients with persistent testicular involvement after Block 1 receive testicular radiation during Block 2.","id":"OG001","title":"Arm D (LR Blinatumomab)"}],"paramType":"NUMBER","populationDescription":"LR patients randomized per protocol. This is the cohort of patients who were included in the primary analysis addressing the primary objective on LR patients. Of the total of 256 randomized LR patients, 1 patient was found to be ineligible and was excluded.","reportingStatus":"POSTED","timeFrame":"Up to 3 years from date of randomization","title":"Overall Survival (OS) of LR Relapse Patients","type":"SECONDARY","unitOfMeasure":"percentage of participants"}